Home
User Guide
What's in a MalaCard Search Guide Our Sources
Analysis Tools
GeneCards GeneAnalytics GeneAlaCart PathCards VarElect TGex
News and Views Disease Lists/Categories
About
About MalaCards Our Publications Weizmann Institute LifeMap Discovery® Terms of Use MalaCards Team
MCID: GLL018
MIFTS: 55

Gallbladder Cancer

Categories: Cancer diseases, Gastrointestinal diseases, Liver diseases, Rare diseases
Genes Variations Tissues Related diseases Publications Pathways Symptoms & Phenotypes Drugs
Sources

Aliases & Classifications for Gallbladder Cancer

About this section

MalaCards integrated aliases for Gallbladder Cancer:

Name: Gallbladder Cancer 12 53 37 55 43 15
Gallbladder Carcinoma 12 55 15 73
Malignant Neoplasm of Gallbladder 12 73
Carcinoma of Gallbladder 12 6
Gallbladder Neoplasm 12 73
Malignant Neoplasm of Gallbladder Localized 73
Localized Malignant Gallbladder Neoplasm 12
Malignant Tumor of the Gallbladder 12
Malignant Tumour of Gallbladder 12
Cancer of the Gallbladder 12
Tumor of the Gallbladder 12
Carcinoma Gallbladder 12
Gallbladder Neoplasms 44
Gallbladder Ca 12

Classifications:

MalaCards categories:
Global: Rare diseases Cancer diseases
Anatomical: Gastrointestinal diseases Liver diseases
See all MalaCards categories (disease lists)
ICD10: 33


External Ids:

Disease Ontology 12 DOID:3121 DOID:4948
ICD10 33 C23
ICD9CM 35 156.0
MeSH 44 D005706
SNOMED-CT 68 93810008
KEGG 37 H00047
Sources

Summaries for Gallbladder Cancer

About this section
MedlinePlus : 43 Your gallbladder is a pear-shaped organ under your liver. It stores bile, a fluid made by your liver to digest fat. As your stomach and intestines digest food, your gallbladder releases bile through a tube called the common bile duct. The duct connects your gallbladder and liver to your small intestine. Cancer of the gallbladder is rare. It is more common in women and Native Americans. Symptoms include Jaundice (yellowing of the skin and whites of the eyes) Pain above the stomach Fever Nausea and vomiting Bloating Lumps in the abdomen It is hard to diagnose gallbladder cancer in its early stages. Sometimes doctors find it when they remove the gallbladder for another reason. But people with gallstones rarely have gallbladder cancer. Because it is often found late, it can be hard to treat gallbladder cancer. Treatment options include surgery, chemotherapy, radiation, or a combination. NIH: National Cancer Institute

MalaCards based summary : Gallbladder Cancer, also known as gallbladder carcinoma, is related to cholangiocarcinoma and adenocarcinoma, and has symptoms including nausea and vomiting, constipation and abdominal pain. An important gene associated with Gallbladder Cancer is PIK3CA (Phosphatidylinositol-4,5-Bisphosphate 3-Kinase Catalytic Subunit Alpha), and among its related pathways/superpathways are MAPK Pathway and DNA Damage Response (only ATM dependent). The drugs Oxaliplatin and Cola have been mentioned in the context of this disorder. Affiliated tissues include liver, lymph node and skin.

Disease Ontology : 12 A biliary tract cancer that is located in the gallbladder.

Wikipedia : 76 Gallbladder cancer is a relatively uncommon cancer.[citation needed] It has peculiar geographical... more...

Sources

Related Diseases for Gallbladder Cancer

About this section

Diseases related to Gallbladder Cancer via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 180)
# Related Disease Score Top Affiliating Genes
1 cholangiocarcinoma 32.2 AFAP1-AS1 ERBB2 H19 MALAT1 PIK3CA TP53
2 adenocarcinoma 30.2 ERBB2 H19 MALAT1 PIK3CA TP53
3 kidney cancer 29.8 H19 HOTAIR MALAT1 MEG3 TP53
4 bladder cancer 29.8 CDKN2B-AS1 ERBB2 H19 HOTAIR MALAT1 MEG3
5 retinoblastoma 29.8 CCAT1 HOTAIR MALAT1 MEG3 TP53
6 squamous cell carcinoma 29.6 CDKN2B-AS1 ERBB2 H19 HOTAIR MALAT1 PIK3CA
7 melanoma 29.3 CDKN2B-AS1 H19 HOTAIR HOXA-AS2 LINC-ROR MALAT1
8 renal cell carcinoma, nonpapillary 29.3 CCAT1 CRNDE CYTOR H19 HOTAIR LINC-ROR
9 hepatocellular carcinoma 29.0 AFAP1-AS1 CCAT1 CDKN2B-AS1 CRNDE CYTOR H19
10 ovarian cancer 28.9 AFAP1-AS1 CCAT1 CDKN2B-AS1 CRNDE ERBB2 H19
11 pancreatic cancer 28.9 AFAP1-AS1 CCAT1 CDKN2B-AS1 CRNDE CYTOR ERBB2
12 lung cancer 28.9 AFAP1-AS1 CCAT1 CDKN2B-AS1 ERBB2 FENDRR H19
13 breast cancer 28.8 CCAT1 CDKN2B-AS1 CRNDE CYTOR ERBB2 H19
14 adenosquamous gallbladder carcinoma 12.4
15 gallbladder small cell carcinoma 11.4
16 bile duct cancer 11.4
17 gallbladder adenocarcinoma 11.1
18 gallbladder squamous cell carcinoma 11.1
19 gallbladder papillary carcinoma 11.1
20 biliary tract neoplasm 11.0
21 cholecystitis 10.5
22 xanthogranulomatous cholecystitis 10.4
23 gastric papillary adenocarcinoma 10.3 ERBB2 TP53
24 adult hepatocellular carcinoma 10.3 PIK3CA TP53
25 uterine corpus serous adenocarcinoma 10.3 ERBB2 PIK3CA TP53
26 carcinoid syndrome 10.3
27 breast squamous cell carcinoma 10.3 ERBB2 PIK3CA TP53
28 rare adenocarcinoma of the breast 10.3 PIK3CA TP53
29 uterine body mixed cancer 10.3 ERBB2 PIK3CA TP53
30 uterine corpus cancer 10.3 ERBB2 PIK3CA TP53
31 malignant spiradenoma 10.3 PIK3CA TP53
32 ovary adenocarcinoma 10.3 ERBB2 PIK3CA TP53
33 esophagus adenocarcinoma 10.3 AFAP1-AS1 ERBB2 TP53
34 ovarian cancer 1 10.3 ERBB2 PIK3CA TP53
35 malignant ovarian surface epithelial-stromal neoplasm 10.3 ERBB2 PIK3CA TP53
36 ovary epithelial cancer 10.3 ERBB2 PIK3CA TP53
37 pleomorphic adenoma carcinoma 10.3 ERBB2 TP53
38 serous cystadenocarcinoma 10.3 ERBB2 PIK3CA TP53
39 cystadenocarcinoma 10.3 ERBB2 PIK3CA TP53
40 endometrial adenocarcinoma 10.3 ERBB2 MALAT1 TP53
41 estrogen-receptor positive breast cancer 10.3 ERBB2 PIK3CA TP53
42 uterine anomalies 10.3 ERBB2 PIK3CA TP53
43 vulva squamous cell carcinoma 10.3 MALAT1 MEG3 TP53
44 functionless pituitary adenoma 10.3 HOTAIR MEG3
45 carcinosarcoma 10.3 ERBB2 PIK3CA TP53
46 marek disease 10.3 H19 TP53
47 ovarian serous cystadenocarcinoma 10.3 ERBB2 PIK3CA TP53
48 respiratory system cancer 10.3 ERBB2 MALAT1 PIK3CA TP53
49 triple-receptor negative breast cancer 10.3 HOTAIR LINC-ROR MALAT1
50 non-proliferative fibrocystic change of the breast 10.3 ERBB2 TP53

Comorbidity relations with Gallbladder Cancer via Phenotypic Disease Network (PDN):


Cholangitis Cholestasis
Deficiency Anemia

Graphical network of the top 20 diseases related to Gallbladder Cancer:



Diseases related to Gallbladder Cancer
Sources

Symptoms & Phenotypes for Gallbladder Cancer

About this section

UMLS symptoms related to Gallbladder Cancer:


nausea and vomiting, constipation, abdominal pain, diarrhea, icterus, dyspepsia, heartburn, gastrointestinal gas
Sources

Drugs & Therapeutics for Gallbladder Cancer

About this section

Drugs for Gallbladder Cancer (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 195)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Oxaliplatin Approved, Investigational Phase 4,Phase 2,Phase 3,Phase 1 61825-94-3 43805 6857599 5310940 9887054
2 Cola Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
3 Liver Extracts Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable
4
Cisplatin Approved Phase 3,Phase 2,Phase 1,Not Applicable 15663-27-1 2767 441203 84093
5
Fluorouracil Approved Phase 3,Phase 2,Phase 1 51-21-8 3385
6
Gemcitabine Approved Phase 3,Phase 2,Phase 1,Not Applicable 95058-81-4 60750
7
Epirubicin Approved Phase 3,Phase 1 56420-45-2 41867
8
Somatostatin Approved, Investigational Phase 3 51110-01-1, 38916-34-6 53481605
9
leucovorin Approved Phase 3,Phase 1,Phase 2 58-05-9 6006 143
10
Trioxsalen Approved Phase 3,Phase 2 3902-71-4 5585
11
Capecitabine Approved, Investigational Phase 3,Phase 2,Phase 1 154361-50-9 60953
12
Fentanyl Approved, Illicit, Investigational, Vet_approved Phase 3 437-38-7 3345
13
Ondansetron Approved Phase 3 99614-02-5 4595
14
Dexamethasone Approved, Investigational, Vet_approved Phase 3 50-02-2 5743
15
Dexamethasone acetate Approved, Investigational, Vet_approved Phase 3 1177-87-3
16
Levoleucovorin Approved, Investigational Phase 3,Phase 2,Phase 1 68538-85-2
17
Magnesium Sulfate Approved, Investigational, Vet_approved Phase 3 7487-88-9 24083
18
Citalopram Approved Phase 3 59729-33-8 2771
19
Folic Acid Approved, Nutraceutical, Vet_approved Phase 3,Phase 1,Phase 2 59-30-3 6037
20 Pancreatic Polypeptide Investigational Phase 3,Phase 2,Phase 1 59763-91-6
21 Immunologic Factors Phase 3,Phase 2,Phase 1,Not Applicable
22 Anti-Bacterial Agents Phase 3,Phase 2,Phase 1
23 Immunosuppressive Agents Phase 3,Phase 2,Phase 1,Not Applicable
24 Antimetabolites Phase 3,Phase 2,Phase 1,Not Applicable
25 Antimetabolites, Antineoplastic Phase 3,Phase 2,Phase 1,Not Applicable
26 Antibiotics, Antitubercular Phase 3,Phase 2,Phase 1
27 Topoisomerase Inhibitors Phase 3,Phase 2,Phase 1
28 Antiviral Agents Phase 3,Phase 2,Phase 1,Not Applicable
29 Anti-Infective Agents Phase 3,Phase 2,Phase 1,Not Applicable
30 Peripheral Nervous System Agents Phase 3,Phase 1
31 Analgesics Phase 3,Phase 1
32 Hormones Phase 3
33 Hormone Antagonists Phase 3
34 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 3
35 Ether Phase 3,Phase 2
36 Photosensitizing Agents Phase 3,Phase 2,Phase 1,Not Applicable
37 Dihematoporphyrin Ether Phase 3,Phase 2
38 Dermatologic Agents Phase 3,Phase 2,Phase 1,Not Applicable
39 Central Nervous System Depressants Phase 3
40 Adjuvants, Anesthesia Phase 3
41 Anesthetics, Intravenous Phase 3
42 Analgesics, Opioid Phase 3
43 Anesthetics, General Phase 3
44 Narcotics Phase 3
45 Anesthetics Phase 3
46 BB 1101 Phase 3
47 Antipruritics Phase 3
48 Serotonin Agents Phase 3,Phase 2
49 Anti-Inflammatory Agents Phase 3
50 Antipsychotic Agents Phase 3

Interventional clinical trials:

(show top 50) (show all 189)
# Name Status NCT ID Phase Drugs
1 Relationship Between Platinum Levels in the Blood and Neurotoxicity in Patients Who Are Receiving Oxaliplatin for Gastrointestinal Cancer Unknown status NCT00274885 Phase 4 oxaliplatin
2 Biliary Metal Stent Study: Metal Stents for Management of Distal Malignant Biliary Obstruction Completed NCT00280709 Phase 4
3 Palliative Biliary Stenting on the Quality of Life of Patients With Unresectable Carcinoma Gallbladder With Hiliar Block. Completed NCT00391183 Phase 2, Phase 3
4 New Chemotherapy Regimen in the Treatment of Advanced Gallbladder Carcinoma Completed NCT01053390 Phase 3 Somatostatin;epirubicin, cisplatin, LV（Leucovorin）、 5-FU（5-Fluorouracil）
5 Biliary Stenting With or Without Photodynamic Therapy in Treating Patients With Locally Advanced, Recurrent, or Metastatic Cholangiocarcinoma or Other Biliary Tract Tumors That Cannot Be Removed by Surgery Completed NCT00513539 Phase 3 porfimer sodium
6 Gemcitabine With or Without Cisplatin in Treating Patients With Unresectable Locally Advanced or Metastatic Cholangiocarcinoma or Other Biliary Tract Tumors Completed NCT00262769 Phase 3 cisplatin;gemcitabine hydrochloride
7 Fluorouracil, Cisplatin, and Radiation Therapy or Gemcitabine and Oxaliplatin in Treating Patients With Nonmetastatic Biliary Tract Cancer That Cannot Be Removed By Surgery Completed NCT00304135 Phase 2, Phase 3 cisplatin;gemcitabine hydrochloride;oxaliplatin
8 Capecitabine or Observation After Surgery in Treating Patients With Biliary Tract Cancer Completed NCT00363584 Phase 3 capecitabine
9 Gemcitabine Hydrochloride and Oxaliplatin or Observation in Treating Patients With Biliary Tract Cancer That Has Been Removed by Surgery Completed NCT01313377 Phase 3 gemcitabine hydrochloride;oxaliplatin
10 Comprehensive Electronic Cancer Support System for the Treatment of Cancer Related Symptoms Completed NCT01640522 Phase 3
11 Fentanyl Sublingual Spray in Treating Patients With Breakthrough Cancer Pain Completed NCT00538850 Phase 3 Fentanyl sublingual spray;Placebo
12 Ondansetron With or Without Dexamethasone to Prevent Vomiting in Patients Receiving Radiation Therapy to the Upper Abdomen Completed NCT00016380 Phase 3 dexamethasone;ondansetron
13 Perioperative Therapy Preoperative Chemotherapy Versus Chemoradiotherapy in Locally Advanced Gall Bladder Cancers Recruiting NCT02867865 Phase 2, Phase 3 Gemcitabine;Cisplatin
14 Adjuvant Chemotherapy With Gemcitabine and Cisplatin Compared to Standard of Care After Curative Intent Resection of Biliary Tract Cancer Recruiting NCT02170090 Phase 3 Gemcitabine;Cisplatin;Capecitabine
15 Clinical Trial of Adjuvant Chemotherapy Followed by Concurrent Chemoradiotherapy Compared With Adjuvant Chemotherapy Alone in Patients With Gallbladder Carcinoma and Extrahepatic Cholangiocarcinoma Recruiting NCT02798510 Phase 3 capecitabine;gemcitabine
16 Adjuvant Chemotherapy for Biliary Tract Cancer After Curative Resection Recruiting NCT03779035 Phase 3 Gemcitabine;Capecitabine
17 Gemcitabine Hydrochloride and Cisplatin With or Without Nab-Paclitaxel in Treating Patients With Newly Diagnosed Advanced Biliary Tract Cancers Recruiting NCT03768414 Phase 3 Cisplatin;Gemcitabine Hydrochloride;Nab-paclitaxel
18 Active Symptom Control Alone or With mFOLFOX Chemotherapy for Locally Advanced/ Metastatic Biliary Tract Cancers Active, not recruiting NCT01926236 Phase 3 L-folinic acid;5 FU;Oxaliplatin
19 Chemotherapy Before & After Surgery in Patients With Resectable Gallbladder Cancer Not yet recruiting NCT03579758 Phase 3 Capecitabine;Cisplatin;Gemcitabine
20 Neoadjuvant Chemotherapy With Gemcitabine Plus Cisplatin Followed by Radical Liver Resection Versus Immediate Radical Liver Resection Alone With or Without Adjuvant Chemotherapy in Incidentally Detected Gallbladder Carcinoma After Simple Cholecystectomy or in Front of Radical Resection of BTC Not yet recruiting NCT03673072 Phase 3 Gemcitabine;Cisplatin;Adjuvant chemotherapy
21 Gemcitabine With or Without Capecitabine in Treating Patients With Locally Advanced, Unresectable, or Metastatic Biliary Cancer Terminated NCT00658593 Phase 3 capecitabine;gemcitabine hydrochloride
22 Escitalopram in Treating Depression in Patients With Advanced Lung or Gastrointestinal Cancer Terminated NCT00387348 Phase 3 escitalopram oxalate;Placebo
23 XL119 Versus 5-Fluorouracil (5-FU) Plus Leucovorin (LV) in Subjects With Advanced Biliary Tumors Terminated NCT00090025 Phase 3 becatecarin;5-Fluorouracil Plus Leucovorin
24 Study to Evaluate the Clinical Benefit Response in Cancer Patients With Advanced Disease With AMT2003 Versus Placebo Terminated NCT00332280 Phase 2, Phase 3 AMT2003
25 Stent Placement With or Without Photodynamic Therapy Using Porfimer Sodium as Palliative Treatment in Treating Patients With Stage III or Stage IV Cholangiocarcinoma That Cannot Be Removed By Surgery Withdrawn NCT00253617 Phase 3 porfimer sodium
26 A Randomized, Open, Prospective Clinical Research of Fluorouracil Implant to Improve Surgical Gallbladder Cancer and Bile Duct Cancer Unknown status NCT01317069 Phase 2 Fluorouracil implant
27 Liposomal Doxorubicin in Treating Patients With Liver or Bile Duct Cancer Unknown status NCT00003296 Phase 2 pegylated liposomal doxorubicin hydrochloride
28 HAI Via Interventionally Implanted Port Catheter Systems Unknown status NCT00356161 Phase 2
29 Gemcitabine, Oxaliplatin and Panitumumab in Kras/B-raf Wild-Type Biliary Track and Gallbladder Cancer Completed NCT01308840 Phase 2 Panitumumab;oxaliplatin;gemcitabine
30 Study of Gemcitabine and Carboplatin in the Treatment of Metastatic or Recurrent Cholangiocarcinoma/Gallbladder Cancer Completed NCT00660140 Phase 2 Gemcitabine;Carboplatin
31 Capecitabine, Oxaliplatin, Bevacizumab and Radiation Therapy in Patients With Biliary Tract and Gallbladder Cancer Completed NCT00142480 Phase 2 Capecitabine;Oxaliplatin;Bevacizumab
32 Gemcitabine and Cisplatin for Gallbladder and Biliary Tract Cancer Completed NCT00123825 Phase 2 Gemcitabine;Cisplatin
33 Gemcitabine Plus Pemetrexed Disodium in Treating Patients With Unresectable or Metastatic Biliary Tract or Gallbladder Cancer Completed NCT00059865 Phase 1, Phase 2 gemcitabine hydrochloride;pemetrexed disodium
34 Combination Chemotherapy in Treating Patients With Unresectable or Metastatic Biliary Tract or Gallbladder Cancer Completed NCT00009893 Phase 2 fluorouracil;gemcitabine hydrochloride;leucovorin calcium
35 S0514 Sorafenib in Treating Patients With Unresectable or Metastatic Gallbladder Cancer or Cholangiocarcinoma Completed NCT00238212 Phase 2 sorafenib tosylate
36 S0202 Gemcitabine and Capecitabine for Unresectable Locally Advanced Metastatic Gallbladder Cancer or Cholangiocarcinoma Completed NCT00033540 Phase 2 capecitabine;gemcitabine hydrochloride
37 Sorafenib Tosylate and Erlotinib Hydrochloride in Treating Patients With Locally Advanced, Unresectable, or Metastatic Gallbladder Cancer or Cholangiocarcinoma Completed NCT01093222 Phase 2 Erlotinib Hydrochloride;Sorafenib Tosylate
38 Trastuzumab in Treating Patients With Locally Advanced or Metastatic Gallbladder Cancer or Bile Duct Cancer That Cannot Be Removed by Surgery Completed NCT00478140 Phase 2
39 Dolastatin 10 in Treating Patients With Metastatic Or Recurrent Liver, Bile Duct, or Gallbladder Cancer Completed NCT00003557 Phase 2 dolastatin 10
40 Gemcitabine, Oxaliplatin in Combination With Bevacizumab in Biliary Tract and Gallbladder Cancer Completed NCT00361231 Phase 2 Bevacizumab;Gemcitabine;Oxaliplatin
41 Triapine and Gemcitabine Hydrochloride in Gallbladder Cancer Completed NCT00075504 Phase 2 triapine;gemcitabine
42 Trametinib or Combination Chemotherapy in Treating Patients With Refractory or Advanced Biliary or Gallbladder Cancer or That Cannot Be Removed by Surgery Completed NCT02042443 Phase 2 Capecitabine;Fluorouracil;Leucovorin Calcium;Trametinib
43 Irinotecan in Treating Patients With Advanced Gallbladder or Bile Duct Cancer Completed NCT00003276 Phase 2 irinotecan hydrochloride
44 Erlotinib in Treating Patients With Unresectable Liver, Bile Duct, or Gallbladder Cancer Completed NCT00033462 Phase 2 erlotinib hydrochloride
45 Gemcitabine and Capecitabine in Treating Patients With Advanced and/or Inoperable Cholangiocarcinoma or Carcinoma of the Gallbladder Completed NCT00084942 Phase 2 capecitabine;gemcitabine hydrochloride
46 DX-8951f in Treating Patients With Biliary Cancer Completed NCT00005938 Phase 2 exatecan mesylate
47 Oxaliplatin and Capecitabine in Patients With Unresectable Cholangiocarcinoma Completed NCT00338988 Phase 2 Capecitabine;Oxaliplatin
48 Gemcitabine and Cisplatin Plus Sorafenib in Patients With Advanced Biliary Tract Carcinomas Naive to Systemic Therapy Completed NCT00919061 Phase 2 Gemcitabine;Cisplatin;Sorafenib
49 Efficacy of Imatinib and 5-FU/Leucovorin in Patients With Advanced Carcinoma of the Gallbladder and Bile Duct Completed NCT01153750 Phase 2 Glivec
50 Vandetanib Gemcitabine Or Placebo Plus Gemcitabine Or Vandetanib Monotherapy In Advanced Biliary Tract Cancer Completed NCT00753675 Phase 2 ZD6474, Vandetanib;ZD6474, Vandetanib;Gemcitabine;Placebo matching ZD6474

Search NIH Clinical Center for Gallbladder Cancer

Cochrane evidence based reviews: gallbladder neoplasms

Sources

Genetic Tests for Gallbladder Cancer

About this section
Sources

Anatomical Context for Gallbladder Cancer

About this section

MalaCards organs/tissues related to Gallbladder Cancer:

41
Liver, Lymph Node, Skin, Eye, Small Intestine, T Cells, Nk Cells

The Foundational Model of Anatomy Ontology organs/tissues related to Gallbladder Cancer:

19
The Gallbladder
Sources

Publications for Gallbladder Cancer

About this section

Articles related to Gallbladder Cancer:

(show top 50) (show all 1781)
# Title Authors Year
1
Comparison of Laparoscopic and Open Approach in Treating Gallbladder Cancer. ( 30527484 )
2019
2
The incidence rates and survival of gallbladder cancer in the USA. ( 28683010 )
2019
3
EMP3, which is regulated by miR-663a, suppresses gallbladder cancer progression via interference with the MAPK/ERK pathway. ( 29778567 )
2018
4
Apparent diffusion coefficient as a potential marker for tumour differentiation, staging and long-term clinical outcomes in gallbladder cancer. ( 29943183 )
2018
5
RIP1 regulates TNF-I+-mediated lymphangiogenesis and lymphatic metastasis in gallbladder cancer by modulating the NF-I_B-VEGF-C pathway. ( 29844685 )
2018
6
Laparoscopic Surgery for Gallbladder Cancer: An Expert Consensus Statement. ( 29339660 )
2018
7
Intra-arterial chemotherapy improved survival of stage 2-3 gallbladder cancer after curative resection. ( 29872309 )
2018
8
Trends of Gallbladder Cancer in Jordan Over 2 Decades: Where Are We? ( 29760576 )
2018
9
Genomic <i>ERBB2</i>/<i>ERBB3</i> mutations promote PD-L1-mediated immune escape in gallbladder cancer: a whole-exome sequencing analysis. ( 29954840 )
2018
10
Chemoradiotherapy Versus Chemotherapy Alone for Unresected Nonmetastatic Gallbladder Cancer: National Practice Patterns and Outcomes. ( 29295882 )
2018
11
Association of TERT-CLPTM1L and 8q24 Common Genetic Variants with Gallbladder Cancer Susceptibility and Prognosis in North Indian Population. ( 29450669 )
2018
12
Gallbladder cancer - no improvement in survival over time in a Swedish population. ( 29932778 )
2018
13
PLZF inhibits proliferation and metastasis of gallbladder cancer by regulating IFIT2. ( 29358655 )
2018
14
Gallbladder Cancer: Complete Resection after Second Line Treatment in Stage IV Disease. ( 29292472 )
2018
15
Predictive factors for incidental gallbladder cancer (IGBC) in patients undergoing cholecystectomy for presumed benign disease. A single-center experience. ( 29848815 )
2018
16
Research gaps and unanswered questions in gallbladder cancer. ( 29784604 )
2018
17
Laparoscopic management of incidental gallbladder cancer. ( 29926166 )
2018
18
Trends in Gallbladder Cancer Incidence and Survival in Korea. ( 29370591 )
2018
19
Diagnostic accuracy of MDCT in differentiating gallbladder cancer from acute and xanthogranulomatous cholecystitis. ( 29679780 )
2018
20
Knockdown of TRIM31 suppresses proliferation and invasion of gallbladder cancer cells by down-regulating MMP2/9 through the PI3K/Akt signaling pathway. ( 29864908 )
2018
21
miR-433 accelerates acquired chemoresistance of gallbladder cancer cells by targeting cyclin M. ( 29435072 )
2018
22
Association of perioperative transfusion with survival and recurrence after resection of gallbladder cancer: A 10-institution study from the US Extrahepatic Biliary Malignancy Consortium. ( 29761515 )
2018
23
Gallbladder cancer: review of a rare orphan gastrointestinal cancer with a focus on populations of New Mexico. ( 29914418 )
2018
24
Clinicopathological characteristics and outcomes of rare histologic subtypes of gallbladder cancer over two decades: A population-based study. ( 29889907 )
2018
25
Early recurrence after laparoscopic radical cholecystectomy in a patient with gallbladder cancer. ( 29794366 )
2018
26
The emerging roles of long non-coding RNA in gallbladder cancer tumorigenesis. ( 29758925 )
2018
27
Metagenomics of Microbial Communities in Gallbladder Bile from Patients with Gallbladder Cancer or Cholelithiasis ( 29693356 )
2018
28
Indication and Usefulness of Bile Juice Cytology for Diagnosis of Gallbladder Cancer. ( 29849591 )
2018
29
Circular RNA HIPK3 promotes gallbladder cancer cell growth by sponging microRNA-124. ( 29928876 )
2018
30
Clinical Relevance of PD-L1 Expression in Gallbladder Cancer: A Potential Target for Therapy. ( 29882997 )
2018
31
Survey Results of the Expert Meeting on Laparoscopic Surgery for Gallbladder Cancer and a Review of Relevant Literature. ( 29339658 )
2018
32
Cytoplasmic CD133 expression correlates with histologic differentiation and is a significant prognostic factor in extrahepatic bile duct cancer and gallbladder cancer. ( 30405779 )
2018
33
Synchronous cancers of gallbladder carcinoma and combined hepatocellular cholangiocarcinoma: an unusual case and literature review. ( 30373546 )
2018
34
Transglutaminase 2 Mediates the Cytotoxicity of Resveratrol in a Human Cholangiocarcinoma and Gallbladder Cancer Cell Lines. ( 29757003 )
2018
35
Hemocholecyst related to cholecystitis secondary to pseudoaneurysm mimicking gallbladder cancer. ( 30541740 )
2018
36
Plasma Helicobacter pylori Antibody Titers and Helicobacter pylori Infection Positivity Rates in Patients with Gallbladder Cancer or Cholelithiasis: a Hospital-Based Case-Control Study ( 30051672 )
2018
37
c‑Jun suppresses the expression of WNT inhibitory factor 1 through transcriptional regulation and interaction with DNA methyltransferase 1 in gallbladder cancer. ( 29693707 )
2018
38
Outcome of neoadjuvant chemotherapy in "locally advanced/borderline resectable" gallbladder cancer: the need to define indications. ( 29706425 )
2018
39
Clues to predict incidental gallbladder cancer. ( 29709218 )
2018
40
Gallbladder cancer: a journey of a thousand steps. ( 29722272 )
2018
41
The association between preoperative serum interleukin-6 levels and postoperative prognosis in patients with T2 gallbladder cancer. ( 29723410 )
2018
42
Establishment of a Gallbladder Cancer-Specific Survival Model to Predict Prognosis in Non-metastatic Gallbladder Cancer Patients After Surgical Resection. ( 29736837 )
2018
43
Racial/ethnic disparities in gallbladder cancer receipt of treatments. ( 29755774 )
2018
44
High rate of positive lymph nodes in T1a gallbladder cancer does not translate to decreased survival: a population-based, propensity score adjusted analysis. ( 29891423 )
2018
45
Surgical Strategy for T2 Gallbladder Cancer: Nationwide Multicenter Survey in Korea. ( 29983693 )
2018
46
Extent of lymph node dissection in patients with gallbladder cancer. ( 29993120 )
2018
47
Long-term outcomes and prognostic markers in gallbladder cancer. ( 29995783 )
2018
48
DUSP1 enhances the chemoresistance of gallbladder cancer via the modulation of the p38 pathway and DNA damage/repair system. ( 30008878 )
2018
49
Significance of bile duct resection for advanced gallbladder cancer without biliary infiltration. ( 30049437 )
2018
50
Classification of gallbladder cancer by assessment of CD8+ TIL and PD-L1 expression. ( 30055582 )
2018
Sources

Variations for Gallbladder Cancer

About this section

ClinVar genetic disease variations for Gallbladder Cancer:

6 (show all 45)
# Gene Variation Type Significance SNP ID Assembly Location
1 TP53 NM_000546.5(TP53): c.722C> T (p.Ser241Phe) single nucleotide variant Likely pathogenic rs28934573 GRCh37 Chromosome 17, 7577559: 7577559
2 TP53 NM_000546.5(TP53): c.722C> T (p.Ser241Phe) single nucleotide variant Likely pathogenic rs28934573 GRCh38 Chromosome 17, 7674241: 7674241
3 PIK3CA NM_006218.3(PIK3CA): c.1633G> A (p.Glu545Lys) single nucleotide variant Pathogenic/Likely pathogenic rs104886003 GRCh37 Chromosome 3, 178936091: 178936091
4 PIK3CA NM_006218.3(PIK3CA): c.1633G> A (p.Glu545Lys) single nucleotide variant Pathogenic/Likely pathogenic rs104886003 GRCh38 Chromosome 3, 179218303: 179218303
5 PIK3CA NM_006218.3(PIK3CA): c.1633G> A (p.Glu545Lys) single nucleotide variant Pathogenic/Likely pathogenic rs104886003 NCBI36 Chromosome 3, 180418785: 180418785
6 PIK3CA NM_006218.3(PIK3CA): c.1634A> G (p.Glu545Gly) single nucleotide variant Pathogenic/Likely pathogenic rs121913274 GRCh37 Chromosome 3, 178936092: 178936092
7 PIK3CA NM_006218.3(PIK3CA): c.1634A> G (p.Glu545Gly) single nucleotide variant Pathogenic/Likely pathogenic rs121913274 GRCh38 Chromosome 3, 179218304: 179218304
8 PIK3CA NM_006218.3(PIK3CA): c.1634A> C (p.Glu545Ala) single nucleotide variant Pathogenic rs121913274 GRCh37 Chromosome 3, 178936092: 178936092
9 PIK3CA NM_006218.3(PIK3CA): c.1634A> C (p.Glu545Ala) single nucleotide variant Pathogenic rs121913274 GRCh38 Chromosome 3, 179218304: 179218304
10 TP53 NM_000546.5(TP53): c.535C> T (p.His179Tyr) single nucleotide variant Pathogenic/Likely pathogenic rs587780070 GRCh37 Chromosome 17, 7578395: 7578395
11 TP53 NM_000546.5(TP53): c.535C> T (p.His179Tyr) single nucleotide variant Pathogenic/Likely pathogenic rs587780070 GRCh38 Chromosome 17, 7675077: 7675077
12 TP53 NM_000546.5(TP53): c.722C> G (p.Ser241Cys) single nucleotide variant Likely pathogenic rs28934573 GRCh38 Chromosome 17, 7674241: 7674241
13 TP53 NM_000546.5(TP53): c.722C> G (p.Ser241Cys) single nucleotide variant Likely pathogenic rs28934573 GRCh37 Chromosome 17, 7577559: 7577559
14 PIK3CA NM_006218.3(PIK3CA): c.1635G> T (p.Glu545Asp) single nucleotide variant Pathogenic/Likely pathogenic rs121913275 GRCh37 Chromosome 3, 178936093: 178936093
15 PIK3CA NM_006218.3(PIK3CA): c.1635G> T (p.Glu545Asp) single nucleotide variant Pathogenic/Likely pathogenic rs121913275 GRCh38 Chromosome 3, 179218305: 179218305
16 TP53 NM_000546.5(TP53): c.523C> T (p.Arg175Cys) single nucleotide variant Uncertain significance rs138729528 GRCh38 Chromosome 17, 7675089: 7675089
17 TP53 NM_000546.5(TP53): c.523C> T (p.Arg175Cys) single nucleotide variant Uncertain significance rs138729528 GRCh37 Chromosome 17, 7578407: 7578407
18 PIK3CA NM_006218.3(PIK3CA): c.1633G> C (p.Glu545Gln) single nucleotide variant Pathogenic/Likely pathogenic,drug response rs104886003 GRCh37 Chromosome 3, 178936091: 178936091
19 PIK3CA NM_006218.3(PIK3CA): c.1633G> C (p.Glu545Gln) single nucleotide variant Pathogenic/Likely pathogenic,drug response rs104886003 GRCh38 Chromosome 3, 179218303: 179218303
20 ERBB2 NM_004448.3(ERBB2): c.2524G> A (p.Val842Ile) single nucleotide variant Pathogenic/Likely pathogenic rs1057519738 GRCh37 Chromosome 17, 37881332: 37881332
21 ERBB2 NM_004448.3(ERBB2): c.2524G> A (p.Val842Ile) single nucleotide variant Pathogenic/Likely pathogenic rs1057519738 GRCh38 Chromosome 17, 39725079: 39725079
22 ERBB3 NM_001982.3(ERBB3): c.310G> A (p.Val104Met) single nucleotide variant Likely pathogenic rs1057519893 GRCh37 Chromosome 12, 56478854: 56478854
23 ERBB3 NM_001982.3(ERBB3): c.310G> A (p.Val104Met) single nucleotide variant Likely pathogenic rs1057519893 GRCh38 Chromosome 12, 56085070: 56085070
24 ERBB3 NM_001982.3(ERBB3): c.310G> T (p.Val104Leu) single nucleotide variant Likely pathogenic rs1057519893 GRCh37 Chromosome 12, 56478854: 56478854
25 ERBB3 NM_001982.3(ERBB3): c.310G> T (p.Val104Leu) single nucleotide variant Likely pathogenic rs1057519893 GRCh38 Chromosome 12, 56085070: 56085070
26 TP53 NM_000546.5(TP53): c.536A> G (p.His179Arg) single nucleotide variant Uncertain significance rs1057519991 GRCh37 Chromosome 17, 7578394: 7578394
27 TP53 NM_000546.5(TP53): c.536A> G (p.His179Arg) single nucleotide variant Uncertain significance rs1057519991 GRCh38 Chromosome 17, 7675076: 7675076
28 TP53 NM_001126117.1(TP53): c.141T> G (p.His47Gln) single nucleotide variant Likely pathogenic rs876660821 GRCh37 Chromosome 17, 7578393: 7578393
29 TP53 NM_001126117.1(TP53): c.141T> G (p.His47Gln) single nucleotide variant Likely pathogenic rs876660821 GRCh38 Chromosome 17, 7675075: 7675075
30 TP53 NM_000546.5(TP53): c.536A> T (p.His179Leu) single nucleotide variant Uncertain significance rs1057519991 GRCh37 Chromosome 17, 7578394: 7578394
31 TP53 NM_000546.5(TP53): c.536A> T (p.His179Leu) single nucleotide variant Uncertain significance rs1057519991 GRCh38 Chromosome 17, 7675076: 7675076
32 TP53 NM_000546.5(TP53): c.535C> A (p.His179Asn) single nucleotide variant Conflicting interpretations of pathogenicity rs587780070 GRCh37 Chromosome 17, 7578395: 7578395
33 TP53 NM_000546.5(TP53): c.535C> A (p.His179Asn) single nucleotide variant Conflicting interpretations of pathogenicity rs587780070 GRCh38 Chromosome 17, 7675077: 7675077
34 TP53 NM_001126118.1(TP53): c.418C> G (p.His140Asp) single nucleotide variant Likely pathogenic rs587780070 GRCh37 Chromosome 17, 7578395: 7578395
35 TP53 NM_001126118.1(TP53): c.418C> G (p.His140Asp) single nucleotide variant Likely pathogenic rs587780070 GRCh38 Chromosome 17, 7675077: 7675077
36 TP53 NM_001126117.1(TP53): c.140A> C (p.His47Pro) single nucleotide variant Likely pathogenic rs1057519991 GRCh37 Chromosome 17, 7578394: 7578394
37 TP53 NM_001126117.1(TP53): c.140A> C (p.His47Pro) single nucleotide variant Likely pathogenic rs1057519991 GRCh38 Chromosome 17, 7675076: 7675076
38 TP53 NM_000546.5(TP53): c.523C> G (p.Arg175Gly) single nucleotide variant Pathogenic/Likely pathogenic rs138729528 GRCh37 Chromosome 17, 7578407: 7578407
39 TP53 NM_000546.5(TP53): c.523C> G (p.Arg175Gly) single nucleotide variant Pathogenic/Likely pathogenic rs138729528 GRCh38 Chromosome 17, 7675089: 7675089
40 TP53 NM_001126117.1(TP53): c.326C> A (p.Ser109Tyr) single nucleotide variant Likely pathogenic rs28934573 GRCh37 Chromosome 17, 7577559: 7577559
41 TP53 NM_001126117.1(TP53): c.326C> A (p.Ser109Tyr) single nucleotide variant Likely pathogenic rs28934573 GRCh38 Chromosome 17, 7674241: 7674241
42 TP53 NM_001126115.1(TP53): c.325T> C (p.Ser109Pro) single nucleotide variant Likely pathogenic rs1057520002 GRCh37 Chromosome 17, 7577560: 7577560
43 TP53 NM_001126115.1(TP53): c.325T> C (p.Ser109Pro) single nucleotide variant Likely pathogenic rs1057520002 GRCh38 Chromosome 17, 7674242: 7674242
44 TP53 NM_001126114.2(TP53): c.721T> G (p.Ser241Ala) single nucleotide variant Likely pathogenic rs1057520002 GRCh37 Chromosome 17, 7577560: 7577560
45 TP53 NM_001126114.2(TP53): c.721T> G (p.Ser241Ala) single nucleotide variant Likely pathogenic rs1057520002 GRCh38 Chromosome 17, 7674242: 7674242
Sources

Expression for Gallbladder Cancer

About this section
Search GEO for disease gene expression data for Gallbladder Cancer.
Sources

Pathways for Gallbladder Cancer

About this section

Pathways related to Gallbladder Cancer according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1
MAPK Pathway 72
Show member pathways
 11.64 ERBB2 PIK3CA TP53
2
DNA Damage Response (only ATM dependent) 1
11.56 ERBB2 PIK3CA TP53
3
Platinum drug resistance 37
11.3 ERBB2 PIK3CA TP53
4
Pathways Affected in Adenoid Cystic Carcinoma 1
11.15 ERBB2 PIK3CA TP53
5
Central carbon metabolism in cancer 37
10.94 ERBB2 PIK3CA TP53
6
LncRNA-mediated mechanisms of therapeutic resistance 1
10.1 HOTAIR LINC-ROR MEG3 TP53 UCA1
Sources

GO Terms for Gallbladder Cancer

About this section
Sources

Sources for Gallbladder Cancer

About this section
3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
The MalaCards human disease database index: 1-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Content
Loading form....